145 related articles for article (PubMed ID: 11803247)
1. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.
Chi L; Pen YW; Potoczak R; Gibson G; Hicks G; Mertz TE; Janiczek N; Juneau PL; Gallagher K; Leadley R
Pharmacology; 2002 Feb; 64(2):76-83. PubMed ID: 11803247
[TBL] [Abstract][Full Text] [Related]
2. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
McClanahan TB; Hicks GW; Morrison AL; Peng YW; Janiczek-Dolphin N; Mertz TE; Sullivan ME; Morser J; Juneau PL; Leadley R
Eur J Pharmacol; 2001 Dec; 432(2-3):187-94. PubMed ID: 11740955
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
[TBL] [Abstract][Full Text] [Related]
4. Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031).
Post JM; Sullivan ME; Abendschein D; Ewing J; Hinchman JW; Light DR
Thromb Res; 2002 Feb; 105(4):347-52. PubMed ID: 12031830
[TBL] [Abstract][Full Text] [Related]
5. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Abendschein DR; Baum PK; Martin DJ; Vergona R; Post J; Rumennik G; Sullivan ME; Eisenberg PR; Light DR
J Cardiovasc Pharmacol; 2000 May; 35(5):796-805. PubMed ID: 10813384
[TBL] [Abstract][Full Text] [Related]
6. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
9. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
[TBL] [Abstract][Full Text] [Related]
10. Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition.
Karnicki K; McBane RD; Miller RS; Leadley RJ; Morser J; Owen WG; Chesebro JH
J Thromb Haemost; 2004 Dec; 2(12):2162-9. PubMed ID: 15613022
[TBL] [Abstract][Full Text] [Related]
11. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit.
Bostwick JS; Bentley R; Morgan S; Brown K; Chu V; Ewing WR; Spada AP; Pauls H; Perrone MH; Dunwiddie CT; Leadley RJ
Thromb Haemost; 1999 Jan; 81(1):157-60. PubMed ID: 10348709
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
Qiu X; Wang W; Zhao Z; Sun S; Tang L
Eur J Pharmacol; 2018 Oct; 836():50-56. PubMed ID: 30125563
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
17. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Furugohri T; Isobe K; Honda Y; Kamisato-Matsumoto C; Sugiyama N; Nagahara T; Morishima Y; Shibano T
J Thromb Haemost; 2008 Sep; 6(9):1542-9. PubMed ID: 18624979
[TBL] [Abstract][Full Text] [Related]
18. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Wong PC; Crain EJ; Watson CA; Xin B
J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242
[TBL] [Abstract][Full Text] [Related]
19. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa.
Leadley RJ; Morgan SR; Bentley R; Bostwick JS; Kasiewski CJ; Heran C; Chu V; Brown K; Moxey P; Ewing WR; Pauls H; Spada AP; Perrone MH; Dunwiddie CT
J Cardiovasc Pharmacol; 1999 Dec; 34(6):791-9. PubMed ID: 10598121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
